Who will serve on the Data Monitoring Board (DMB), and what will their role be?
Patient safety in the DAPT Study will be monitored throughout the trial by an independent Data Monitoring Board (DMB). The DMB is an independent group of physicians from the fields of cardiology and interventional cardiology and at least one biostatistician, who are not directly involved in the conduct of the DAPT Study. The DMB will review the study enrollment and subject safety (including reported serious adverse events) on a regular basis and will alert the U.S. FDA should a serious safety concern arise. Robert Bonow, M.D., Northwestern Memorial Hospital, Chicago, will chair the DMB.
Related Questions
- Are industrial users (IUs) required to submit monitoring data to the POTW/control authority if samples are collected in addition to samples required by the PFPR regulation?
- How do I display the SQL Monitoring data for a monitored execution?
- Is the longitudinal panel data available for Monitoring the Future?
